These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

797 related items for PubMed ID: 18389089

  • 1. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N.
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [Abstract] [Full Text] [Related]

  • 2. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C, Barrail A, Goujard C, Taburet AM.
    Clin Pharmacokinet; 2005 Feb; 44(10):1035-50. PubMed ID: 16176117
    [Abstract] [Full Text] [Related]

  • 3. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N.
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [Abstract] [Full Text] [Related]

  • 4. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS, Goa KL.
    Drugs; 2003 Apr; 63(8):769-802. PubMed ID: 12662125
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
    Horberg M, Klein D, Hurley L, Silverberg M, Towner W, Antoniskis D, Kovach D, Mogyoros M, Blake W, Dobrinich R, Dodge W.
    HIV Clin Trials; 2008 Apr; 9(6):367-74. PubMed ID: 19203902
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
    Santoro MM, Bertoli A, Lorenzini P, Lazzarin A, Esposito R, Carosi G, Di Perri G, Filice G, Moroni M, Rizzardini G, Caramello P, Maserati R, Narciso P, Cargnel A, Antinori A, Perno CF, CARe Study Group.
    AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
    [Abstract] [Full Text] [Related]

  • 11. Atazanavir: a review of its use in the management of HIV-1 infection.
    Croom KF, Dhillon S, Keam SJ.
    Drugs; 2009 May 29; 69(8):1107-40. PubMed ID: 19496633
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group.
    Clin Infect Dis; 2007 Jun 01; 44(11):1484-92. PubMed ID: 17479947
    [Abstract] [Full Text] [Related]

  • 14. Atazanavir.
    Orrick JJ, Steinhart CR.
    Ann Pharmacother; 2004 Oct 01; 38(10):1664-74. PubMed ID: 15353575
    [Abstract] [Full Text] [Related]

  • 15. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A.
    J Antimicrob Chemother; 2013 Jun 01; 68(6):1364-72. PubMed ID: 23372058
    [Abstract] [Full Text] [Related]

  • 16. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW, AIDS Clinical Trials Group 5201 Study Team.
    JAMA; 2006 Aug 16; 296(7):806-14. PubMed ID: 16905786
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 16; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Atazanavir: A novel once-daily protease inhibitor.
    Piliero PJ.
    Drugs Today (Barc); 2004 Nov 16; 40(11):901-12. PubMed ID: 15645003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.